Literature DB >> 11230707

Expression of p53 protein in T- and natural killer-cell lymphomas is associated with some clinicopathologic entities but rarely related to p53 mutations.

B Petit1, K Leroy, P Kanavaros, M L Boulland, M Druet-Cabanac, C Haioun, D Bordessoule, P Gaulard.   

Abstract

To determine if p53 abnormalities could be involved in the pathogenesis of T- or natural killer (NK)-cell lymphomas, we investigated 51 cases of these lymphomas for the expression of p53 and its relationship with p53 gene mutations, the expression of the p21 protein as well as the proliferative and apoptotic indices. Overexpression of p53 was found in 19 cases (37%), whereas mutations of the p53 gene were observed in only 5 of 28 tested cases. The analysis of immunohistochemical data showed some entity-related phenotypic profiles. Anaplastic large cell lymphomas showed a frequent overexpression of p53 (7/8 cases) and p21 (6/8 cases) proteins and rare p53 mutations (1/7 cases), suggesting accumulation of a functional wild type p53 protein able to induce p21 expression. Nodal peripheral T-cell lymphomas unspecified showed relatively frequent overexpression of p53 protein (5/7 cases), infrequent p21 expression (2/7 cases), and rare p53 gene mutations (1/6 cases). In angioimmunoblastic lymphomas, the common phenotype was p53-/p21- (15/17 cases), with only a few scattered p53-positive cells, which, on the basis of double staining results, were mostly Epstein-Barr virus-infected B cells. A p53 gene mutation was only found in 1 case (1/8 cases) of angioimmunoblastic lymphoma, which showed cytologic tumor progression. Mycosis fungoides showed p53 overexpression in 2 of 4 cases, including 1 case with p53 gene mutation and features of cytologic tumor progression. Nasal NK/T lymphomas showed p53 overexpression in 2 of 5 cases, 1 of which had a p53 gene mutation. Finally, all lymphoblastic T-cell lymphomas (5 cases) and gammadelta hepatosplenic T-cell lymphomas (3 cases) were negative for expression of p53 and p21 proteins. We conclude that p53 protein overexpression is a common finding in some entities of T- and T/NK-cell lymphomas, whereas a p53 gene mutation is a rare, sporadic, and rather late event associated with tumor progression in some instances. The p53/p21 expression pattern appears to be variable in T- and T/NK-cell lymphoma entities, reinforcing the concept of distinct, entity-related mechanisms of pathogenesis in these tumors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11230707     DOI: 10.1053/hupa.2001.21569

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  11 in total

1.  p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease.

Authors:  L Quintanilla-Martinez; M Kremer; G Keller; M Nathrath; A Gamboa-Dominguez; A Meneses; L Luna-Contreras; A Cabras; H Hoefler; A Mohar; F Fend
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

Review 2.  Natural killer-cell neoplasms.

Authors:  John P Greer; Claudio A Mosse
Journal:  Curr Hematol Malig Rep       Date:  2009-10       Impact factor: 3.952

3.  Restructuring of the dinucleotide-binding fold in an NADP(H) sensor protein.

Authors:  Xiaofeng Zheng; Xueyu Dai; Yanmei Zhao; Qiang Chen; Fei Lu; Deqiang Yao; Quan Yu; Xinping Liu; Chuanmao Zhang; Xiaocheng Gu; Ming Luo
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-11       Impact factor: 11.205

4.  Lymphoepithelioma-like carcinoma of the bladder: three cases with clinicopathological and p53 protein expression study.

Authors:  Francisco Miguel Izquierdo-García; Fructuoso García-Díez; Isabel Fernández; Alberto Pérez-Rosado; Anabel Sáez; Dimas Suárez-Vilela; Rafael Guerreiro-González; Manuel Benéitez-Alvarez
Journal:  Virchows Arch       Date:  2004-04-06       Impact factor: 4.064

5.  Mutation of the p53 tumour suppressor gene and overexpression of its protein in 62 Japanese non-Hodgkin's lymphomas.

Authors:  H Kamata; S Mitani; M Fujiwara; N Aoki; S Okada; S Mori
Journal:  Clin Exp Med       Date:  2007-07-04       Impact factor: 3.984

6.  Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.

Authors:  George Vasmatzis; Sarah H Johnson; Ryan A Knudson; Rhett P Ketterling; Esteban Braggio; Rafael Fonseca; David S Viswanatha; Mark E Law; N Sertac Kip; Nazan Ozsan; Stefan K Grebe; Lori A Frederick; Bruce W Eckloff; E Aubrey Thompson; Marshall E Kadin; Dragana Milosevic; Julie C Porcher; Yan W Asmann; David I Smith; Irina V Kovtun; Stephen M Ansell; Ahmet Dogan; Andrew L Feldman
Journal:  Blood       Date:  2012-08-01       Impact factor: 22.113

7.  An A91V SNP in the perforin gene is frequently found in NK/T-cell lymphomas.

Authors:  Rebeca Manso; Socorro María Rodríguez-Pinilla; Luis Lombardia; Gorka Ruiz de Garibay; Maria Del Mar López; Luis Requena; Lydia Sánchez; Margarita Sánchez-Beato; Miguel Ángel Piris
Journal:  PLoS One       Date:  2014-03-14       Impact factor: 3.240

8.  Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis.

Authors:  J H Schatz; S M Horwitz; J Teruya-Feldstein; M A Lunning; A Viale; K Huberman; N D Socci; N Lailler; A Heguy; I Dolgalev; J C Migliacci; M Pirun; M L Palomba; D M Weinstock; H-G Wendel
Journal:  Leukemia       Date:  2014-09-03       Impact factor: 11.528

9.  The homeoprotein Dlx5 drives murine T-cell lymphomagenesis by directly transactivating Notch and upregulating Akt signaling.

Authors:  Yinfei Tan; Eleonora Sementino; Jinfei Xu; Jianming Pei; Zemin Liu; Timothy K Ito; Kathy Q Cai; Suraj Peri; Andres J P Klein-Szanto; David L Wiest; Joseph R Testa
Journal:  Oncotarget       Date:  2017-02-28

10.  TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: Evidence from a meta-analysis.

Authors:  Peipei Xu; Xu Liu; Jian Ouyang; Bing Chen
Journal:  PLoS One       Date:  2017-04-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.